West Cancer Center

ENDOMETRIAL: ANY STAGE: ADJUVANT: CHEMO-NAIVE: HER2+: NRG-GY026

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Endometrial, uterine

Stage

Stage 3

Phase

Phase 3

Status

Open to Enrollment

Line Of Therapy

1st Line

Investigational Agent

Trastuzumab or trastuzumab/pertuzumab

Drug Class

HER2 antibody

Todd Tillmanns, MD

Sponsor

NRG Oncology

Path

Serous carcinoma or carcinosarcoma

Key Eligibility Criteria Details

FIGO 2009 stage IA-IVB non-recurrent, chemo-naive, HER2-positive endometrial serous carcinoma or carcinosarcoma
Measurable or no-measurable disease allowed
ECOG PS 0-2
No prior chemo, biologic therapy, or targeted thearpy for treatment of endometrial cancer
No prior radiation therapy for endometrial cancer
No planned radiation
No significant cardiac, lung, or intercurrent illness
Patients with prior treatment with hormonal therapy are allowed

ENDOMETRIAL: ADVANCED: MAINTENANCE: p53 WT: XPORT-EC-042

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

VIEW TRIAL ON CLINICALTRIALS.GOV

Malignancy

Endometrial

Stage

Stage 4

Phase

Phase 3

Status

Open to Enrollment

Line Of Therapy

Maintenance

Investigational Agent

Selinexor

Drug Class

Selective inhibitor of nuclear export (SINE)

Todd Tillmanns, MD

Sponsor

Karyopharm Therapeutics, Inc

Path

Endometrioid, serous, undifferentiated, or carcinosarcoma

Key Eligibility Criteria Details

Histologically confirmed EC including: endometrioid, serous, undifferentiated, and carcinomsarcoma
TP53 WT assessed by NGS via central vendor
Completed a single line, at least 12 weeks, of platinum-based therapy (not including adjuvant or neoadjuvant tx for Stage 1-II disease) adn achieved confirmed PR or CR by RECIST.
If Primary Stage IV, may have had surgery or not. If surgery, must have had R0 or R1 resection
Must be able to initiate study drug 3-8 weeks following completion of final dose of chemo
ECOG PS 0-1
No uterine sarcoma
No concurrent systemic steroid therapy above 10mg prednisone or equivalent
No previous treatment with an XPO1 inhibitor
No active brain mets